Merck & Company (MRK) 60.48 $MRK
SmarTrend Watching for Potential Pullback in Shares of Merck After 1.15% Gain
Comtex SmarTrend(R) - Wed Sep 03, 3:42PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $60.06 to a high of $60.86. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $60.42 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 03, 3:41PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $60.06 to a high of $60.86. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $60.42 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Dow Today: Merck (MRK) Leads The Day Higher, Caterpillar (CAT) Lags
at The Street - Wed Sep 03, 3:30PM CDT
The Dow component that led the way higher today was Merck (NYSE:MRK), which sported a 69-cent gain (+1.1%) bringing the stock to $60.48. Holding the Dow back today was Caterpillar (NYSE:CAT), which lagged the broader Dow index with a 46-cent decline...
Tetraphase (TTPH) Up on IGNITE 2 Results on Eravacycline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 12:13PM CDT
Shares of Tetraphase Pharmaceuticals, Inc. (TTPH) were up as the company reported positive top-line results on its lead pipeline candidate, eravacycline.
Global Anti-Coccidial Drugs Market In Animal Health - Global Trends And Forecasts 2014-19
M2 - Wed Sep 03, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snk76v/global) has announced the addition of the "Global Anti-Coccidial Drugs Market In Animal Health - Global Trends And Forecasts - (2014-19)" report to their offering. The increase in global population and also in the per capita global consumption of meat, the increased adoption of intensive farming methods is estimated to drive the market for anticoccidials to $24.33 billion by the year 2020. The Asia pacific region is set to be the highest contributor in terms of total revenue in this market by the year 2020. The countries set to be major contributors from this region are China, India, Japan, Australia etc. The growth in the North American and European markets is set to be stagnant due to the stagnated market and government restrictions. In the veterinary antibiotic market the market for food producing animals account for nearly 80 % of the total market in 2011 this has increased the demand for anticoccidial drugs, largely due to the increased incidences of coccidiosis and other protozoan parasite based diseases that infects majorly food producing organism but are not limited to them. In poultry and cattle markets the incidence of coccidiosis has cost the millions of dollars in treatment and preventive care being given. Also the trend of owning companion animals is also contributing to the increasing use of anitcoccidials, as dogs , cats and occasionally even horses are prone to coccidiosis and if left untreated it could lead to the death of the animal The Market research report titled Global Anticoccidial market- Analysis and future forecast' categorizes the global anticoccidial market on the basis of animal type and geography; forecasting the revenues and analyzing the trends in each of the following submarkets. Key Topics Covered: 1. Introduction 2. Market Defenition 3. Market Drivers 4. Market Restraints 5. Market opportunities 6. Anti Coccidial drugs 7. Region wise analysis of anticoccidial market ( Market size, Forecast and CAGR) 8. Segmentation by Animal Type - anticoccidial market ( Market size, Forecast and CAGR) 9 The future of anticoccidial market 10 Competitive Landscape 11 Company Profiles - Zoetis - Elanco - Merial - Bayer Health care Animal Healthcare division - Merck Animal Healthcares - Boehringer Ingolheim Animal Health - Virbac - Novartis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/snk76v/global
Research and Markets: Global Animal Health Market 2014-2018: Key Vendors Dominating are Bayer, Elanco, Merck Animal Health, Merial & Zoetis
Business Wire - Wed Sep 03, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9rmp67/global_animal) has announced the addition of the "Global Animal Health Market 2014-2018" report to their offering.
Global Animal Health Market 2014-2018: Key Vendors Dominating are Bayer, Elanco, Merck Animal Health, Merial & Zoetis
M2 - Wed Sep 03, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5pw2sr/global_animal) has announced the addition of the "Global Animal Health Market 2014-2018" report to their offering. The Global Animal Health market to grow at a CAGR of 5.43% over the period 2013-2018. Animal feed additives improve the health of animals and the quality of animal food. Animal pharmaceuticals and animal vaccines are used to treat or prevent a disease/condition. Animal diagnostics help in the detection of bacteria, antibodies, viruses, and hormones. Increasing number of mergers and acquisitions is one of the potential trends emerging in the market. M&As provide financial assistance to smaller companies, increase the product portfolio of the acquirer, and rise the distribution channels of companies and help in increasing the presence of global players in the local markets. According to the report, the demand for animal food and protein-rich diet is one of the major drivers in the market. The increase in consumption of animal food by humans necessitates the need for increasing the yield of animal products intensifying market growth consequently. Further, the report states that one of the main challenges faced by the market is the regulatory pitfalls that hamper the development and approval process of a drug, thereby delaying its market entry. To calculate the market size, the report considers revenue generated through the sales of various animal health products through the following segments: - Diagnostics - Pharmaceuticals - Vaccines - Feed Additives Key Vendors - Bayer - Elanco - Merck Animal Health - Merial - Zoetis Other Prominent Vendors - Biogenesis Bago - Boehringer Ingelheim - Ceva Holdings - Heska - Imugene - Indian Immunologicals - Lohmann Animal Health - Neogen - Thermo Fisher Scientific - V?toquinol - Virbac Market Drivers/Challenges/Trends - Growing Demand for Animal Food and Protein-rich Diet - Regulatory Pitfalls - Increase in Mergers & Acquisitions Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/5p...bal_animal
Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in Children with PKU Below 4 Years of Age
PR Newswire Europe - Wed Sep 03, 5:05AM CDT
DARMSTADT, Germany, September 3, 2014 /PRNewswire/ --
This New Novartis AG Drug May Revolutionize Heart Failure Treatment
Todd Campbell, The Motley Fool - Motley Fool - Tue Sep 02, 4:13PM CDT
Doctors have long struggled to effectively treat heart failure caused by high blood pressure. ACE inhibitors, like enalapril -- formerly sold by Merck as the branded drug Vasotec, came on the scene in the 1990s, and ARB inhibitors, like Novartis'...
Regeneron/Sanofi Presents Encouraging Alirocumab Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 3:30PM CDT
Regeneron (REGN) and Sanofi (SNY) announced encouraging results from four phase III studies on alirocumab.
Is It Time to Buy Pfizer Inc.'s Stock?
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:32PM CDT
Since the recession ended, shareholders in Pfizer , the world's largest pharmaceutical company by revenue, have seen their shares more than double. A combination of high-branded drug margins coupled with the expectation that the Affordable Care...
United States Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth
M2 - Tue Sep 02, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dwc7rr/the_us_anti) has announced the addition of the "The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth" report to their offering. The report titled "The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth" provides a comprehensive analysis on the Anti Cancer Drug market in the US covering various aspects such as market size of the industry, market segmentation by Patented and Generic drugs, by type of cancer (blood cancer, breast cancer, lung cancer, pancreatic cancer, colon cancer) and by Oral and Injectable Drugs. The report also provides statistics and information on the government regulations, growth drivers and market shares of major players and brands in the market. The report also entails competitive landscape and profiles of the major players operating in the market. The future projections are included to provide an insight on the prospects in the US Anti Cancer Drug Market. Key Topics Covered In The Report: - The market size of the US anti cancer drug market on the basis of sales, number of drugs in development and number of drugs approved. - The breast cancer, lung cancer, pancreatic cancer, colon cancer, blood and brain cancer drug market - Market segmentation of the US anti cancer drug market on the basis of Type of Therapies, Orals and Injectables and by Generic and Patented Drugs - Government Regulations in the US Anti Cancer Drug Market. - Competitive landscape and detailed company profiles of the major players operating in the pesticides business in US - Revenues of Major Players in US Anti Cancer Drugs Market. - Future outlook and projections of US Anti Cancer Drugs Market, on the basis of anti cancer drug sales in the US. Key Topics Covered: 1. Anti-Cancer Drugs Market Introduction 2. Prevalence of Different types of Cancers in the US 4. The US Anti-cancer Drug Market Segmentation 5. The US Blood Cancer Drug Market Introduction 6. The US Breast Cancer Drugs Market Introduction 7. The US Colon Cancer Drugs Market Introduction 8. The US Brain Cancer Drugs Market Introduction 9. The US Lung Cancer Drugs Market Introduction 10. The US Pancreatic Cancer Drugs Market Introduction 11. Trends and Developments 12. Regulations in the US Anti-cancer Drug Market 13. SWOT Analysis 14. Growth Drivers and Restraints 15. The US Anti-Cancer Drugs Industry Competitive Landscape 16. Company Profiles 17. The US Anti-Cancer Drug Market Future Outlook 18. Macro-Economic Factors Affecting the US Anti-Cancer Drugs Market 19. Appendix Companies Mentioned - Amgen - Astra Zeneca - Bristol Myers - Celgene - Eli Lilly - GlaxoSmithKline - Merck & Co - Novartis - Pfizer - Roche - Sanofi Aventis For more information visit http://www.researchandmarkets.com/research/dw...he_us_anti
Merck (MRK) Approaches New Downside Target of $59.53
Comtex SmarTrend(R) - Tue Sep 02, 9:01AM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $60.12 today and has reached the first level of support at $59.82. Investors may be interested in a cross of the next downside pivot targets of $59.53 and $58.94.
Reveal Insider Trading for Facebook, Plug Power, Achillion Pharmaceuticals, Apple, Twitter, and Intel
PR Newswire - Tue Sep 02, 7:55AM CDT
Today, Insiderslab.com revealed the latest insider trading research for Facebook (NASDAQ: FB), Plug Power (NASDAQ: PLUG), Achillion Pharmaceuticals (NASDAQ: ACHN), Apple (NASDAQ: AAPL), Twitter (NYSE: TWTR), and Intel (NASDAQ:INTC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.
Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company's Investigational Anti-PD-1 Antibody, at ESMO 2014
Business Wire - Tue Sep 02, 7:30AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company's investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 - 30. Data on pembrolizumab are planned to be presented in five advanced solid tumor types, including the first presentation of data evaluating pembrolizumab for the treatment of gastric and bladder (urothelial tract) cancers. Three late-breaking abstracts have been accepted for oral presentation.
Great Cholesterol Drug Data From Regeneron Pharmaceuticals Inc. and Sanofi SA, but Read the Fine Pri
Brian Orelli, The Motley Fool - Motley Fool - Tue Sep 02, 7:00AM CDT
Amgen is leading the race to bring the first anti-PCSK9 cholesterol-lowering drug on the market, having submitted its application for evolocumab to the FDA last week. But Regeneron Pharmaceuticals and Sanofi look like they might have the...
Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical
M2 - Mon Sep 01, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfkpw2/global_multiple) has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. The Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis. One of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis. According to the report, the launch of products for treating multiple sclerosis is expected to drive the market during the forecast period of 2013-2018. There is a lucrative space for companies that can address the issue of unmet medical needs in the market. Further, the report states that one of the major challenges in the Global Multiple Sclerosis Drugs market is the unknown etiology of the disease. This has made difficult for medical researchers to develop drugs that target the main source of the disease. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Market Drivers/Challenges/Trends - Unmet Medical Needs - Unknown Etiology of the Disease - Introduction of Disease-modifying Drugs Key Vendors - Bayer - Biogen Idec - Merck Serono - Novartis - Teva Pharmaceutical Other Prominent Vendors - AB Science - Abbvie - Acorda - Active Biotech - GlaxoSmithKline - Glenmark - Mitsubishi Tanabe - Opexa - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/vf...l_multiple
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Dow 30 Stock Roundup: UTX Reiterates Guidance, BA Wins $8.8B Order - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Aug 29, 10:16AM CDT
The Dow had a mixed week following mixed earnings results and concerns about the situation in Ukraine.
Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical
PR Newswire Europe - Fri Aug 29, 7:37AM CDT
DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/z9b74c/global_multiple] has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/z9b74c/global_multiple] report to their offering.
SmarTrend Watching for Potential Pullback in Shares of Merck After 1.15% Gain
Comtex SmarTrend(R) - Wed Sep 03, 3:42PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $60.06 to a high of $60.86. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $60.42 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 1.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 03, 3:41PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $60.06 to a high of $60.86. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $60.42 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Dow Today: Merck (MRK) Leads The Day Higher, Caterpillar (CAT) Lags
at The Street - Wed Sep 03, 3:30PM CDT
The Dow component that led the way higher today was Merck (NYSE:MRK), which sported a 69-cent gain (+1.1%) bringing the stock to $60.48. Holding the Dow back today was Caterpillar (NYSE:CAT), which lagged the broader Dow index with a 46-cent decline...
Tetraphase (TTPH) Up on IGNITE 2 Results on Eravacycline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 12:13PM CDT
Shares of Tetraphase Pharmaceuticals, Inc. (TTPH) were up as the company reported positive top-line results on its lead pipeline candidate, eravacycline.
Global Anti-Coccidial Drugs Market In Animal Health - Global Trends And Forecasts 2014-19
M2 - Wed Sep 03, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snk76v/global) has announced the addition of the "Global Anti-Coccidial Drugs Market In Animal Health - Global Trends And Forecasts - (2014-19)" report to their offering. The increase in global population and also in the per capita global consumption of meat, the increased adoption of intensive farming methods is estimated to drive the market for anticoccidials to $24.33 billion by the year 2020. The Asia pacific region is set to be the highest contributor in terms of total revenue in this market by the year 2020. The countries set to be major contributors from this region are China, India, Japan, Australia etc. The growth in the North American and European markets is set to be stagnant due to the stagnated market and government restrictions. In the veterinary antibiotic market the market for food producing animals account for nearly 80 % of the total market in 2011 this has increased the demand for anticoccidial drugs, largely due to the increased incidences of coccidiosis and other protozoan parasite based diseases that infects majorly food producing organism but are not limited to them. In poultry and cattle markets the incidence of coccidiosis has cost the millions of dollars in treatment and preventive care being given. Also the trend of owning companion animals is also contributing to the increasing use of anitcoccidials, as dogs , cats and occasionally even horses are prone to coccidiosis and if left untreated it could lead to the death of the animal The Market research report titled Global Anticoccidial market- Analysis and future forecast' categorizes the global anticoccidial market on the basis of animal type and geography; forecasting the revenues and analyzing the trends in each of the following submarkets. Key Topics Covered: 1. Introduction 2. Market Defenition 3. Market Drivers 4. Market Restraints 5. Market opportunities 6. Anti Coccidial drugs 7. Region wise analysis of anticoccidial market ( Market size, Forecast and CAGR) 8. Segmentation by Animal Type - anticoccidial market ( Market size, Forecast and CAGR) 9 The future of anticoccidial market 10 Competitive Landscape 11 Company Profiles - Zoetis - Elanco - Merial - Bayer Health care Animal Healthcare division - Merck Animal Healthcares - Boehringer Ingolheim Animal Health - Virbac - Novartis Animal Healthcare For more information visit http://www.researchandmarkets.com/research/snk76v/global
Research and Markets: Global Animal Health Market 2014-2018: Key Vendors Dominating are Bayer, Elanco, Merck Animal Health, Merial & Zoetis
Business Wire - Wed Sep 03, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9rmp67/global_animal) has announced the addition of the "Global Animal Health Market 2014-2018" report to their offering.
Global Animal Health Market 2014-2018: Key Vendors Dominating are Bayer, Elanco, Merck Animal Health, Merial & Zoetis
M2 - Wed Sep 03, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5pw2sr/global_animal) has announced the addition of the "Global Animal Health Market 2014-2018" report to their offering. The Global Animal Health market to grow at a CAGR of 5.43% over the period 2013-2018. Animal feed additives improve the health of animals and the quality of animal food. Animal pharmaceuticals and animal vaccines are used to treat or prevent a disease/condition. Animal diagnostics help in the detection of bacteria, antibodies, viruses, and hormones. Increasing number of mergers and acquisitions is one of the potential trends emerging in the market. M&As provide financial assistance to smaller companies, increase the product portfolio of the acquirer, and rise the distribution channels of companies and help in increasing the presence of global players in the local markets. According to the report, the demand for animal food and protein-rich diet is one of the major drivers in the market. The increase in consumption of animal food by humans necessitates the need for increasing the yield of animal products intensifying market growth consequently. Further, the report states that one of the main challenges faced by the market is the regulatory pitfalls that hamper the development and approval process of a drug, thereby delaying its market entry. To calculate the market size, the report considers revenue generated through the sales of various animal health products through the following segments: - Diagnostics - Pharmaceuticals - Vaccines - Feed Additives Key Vendors - Bayer - Elanco - Merck Animal Health - Merial - Zoetis Other Prominent Vendors - Biogenesis Bago - Boehringer Ingelheim - Ceva Holdings - Heska - Imugene - Indian Immunologicals - Lohmann Animal Health - Neogen - Thermo Fisher Scientific - V?toquinol - Virbac Market Drivers/Challenges/Trends - Growing Demand for Animal Food and Protein-rich Diet - Regulatory Pitfalls - Increase in Mergers & Acquisitions Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/5p...bal_animal
Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in Children with PKU Below 4 Years of Age
PR Newswire Europe - Wed Sep 03, 5:05AM CDT
DARMSTADT, Germany, September 3, 2014 /PRNewswire/ --
This New Novartis AG Drug May Revolutionize Heart Failure Treatment
Todd Campbell, The Motley Fool - Motley Fool - Tue Sep 02, 4:13PM CDT
Doctors have long struggled to effectively treat heart failure caused by high blood pressure. ACE inhibitors, like enalapril -- formerly sold by Merck as the branded drug Vasotec, came on the scene in the 1990s, and ARB inhibitors, like Novartis'...
Regeneron/Sanofi Presents Encouraging Alirocumab Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 3:30PM CDT
Regeneron (REGN) and Sanofi (SNY) announced encouraging results from four phase III studies on alirocumab.
Is It Time to Buy Pfizer Inc.'s Stock?
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 02, 12:32PM CDT
Since the recession ended, shareholders in Pfizer , the world's largest pharmaceutical company by revenue, have seen their shares more than double. A combination of high-branded drug margins coupled with the expectation that the Affordable Care...
United States Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth
M2 - Tue Sep 02, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dwc7rr/the_us_anti) has announced the addition of the "The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth" report to their offering. The report titled "The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth" provides a comprehensive analysis on the Anti Cancer Drug market in the US covering various aspects such as market size of the industry, market segmentation by Patented and Generic drugs, by type of cancer (blood cancer, breast cancer, lung cancer, pancreatic cancer, colon cancer) and by Oral and Injectable Drugs. The report also provides statistics and information on the government regulations, growth drivers and market shares of major players and brands in the market. The report also entails competitive landscape and profiles of the major players operating in the market. The future projections are included to provide an insight on the prospects in the US Anti Cancer Drug Market. Key Topics Covered In The Report: - The market size of the US anti cancer drug market on the basis of sales, number of drugs in development and number of drugs approved. - The breast cancer, lung cancer, pancreatic cancer, colon cancer, blood and brain cancer drug market - Market segmentation of the US anti cancer drug market on the basis of Type of Therapies, Orals and Injectables and by Generic and Patented Drugs - Government Regulations in the US Anti Cancer Drug Market. - Competitive landscape and detailed company profiles of the major players operating in the pesticides business in US - Revenues of Major Players in US Anti Cancer Drugs Market. - Future outlook and projections of US Anti Cancer Drugs Market, on the basis of anti cancer drug sales in the US. Key Topics Covered: 1. Anti-Cancer Drugs Market Introduction 2. Prevalence of Different types of Cancers in the US 4. The US Anti-cancer Drug Market Segmentation 5. The US Blood Cancer Drug Market Introduction 6. The US Breast Cancer Drugs Market Introduction 7. The US Colon Cancer Drugs Market Introduction 8. The US Brain Cancer Drugs Market Introduction 9. The US Lung Cancer Drugs Market Introduction 10. The US Pancreatic Cancer Drugs Market Introduction 11. Trends and Developments 12. Regulations in the US Anti-cancer Drug Market 13. SWOT Analysis 14. Growth Drivers and Restraints 15. The US Anti-Cancer Drugs Industry Competitive Landscape 16. Company Profiles 17. The US Anti-Cancer Drug Market Future Outlook 18. Macro-Economic Factors Affecting the US Anti-Cancer Drugs Market 19. Appendix Companies Mentioned - Amgen - Astra Zeneca - Bristol Myers - Celgene - Eli Lilly - GlaxoSmithKline - Merck & Co - Novartis - Pfizer - Roche - Sanofi Aventis For more information visit http://www.researchandmarkets.com/research/dw...he_us_anti
Merck (MRK) Approaches New Downside Target of $59.53
Comtex SmarTrend(R) - Tue Sep 02, 9:01AM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $60.12 today and has reached the first level of support at $59.82. Investors may be interested in a cross of the next downside pivot targets of $59.53 and $58.94.
Reveal Insider Trading for Facebook, Plug Power, Achillion Pharmaceuticals, Apple, Twitter, and Intel
PR Newswire - Tue Sep 02, 7:55AM CDT
Today, Insiderslab.com revealed the latest insider trading research for Facebook (NASDAQ: FB), Plug Power (NASDAQ: PLUG), Achillion Pharmaceuticals (NASDAQ: ACHN), Apple (NASDAQ: AAPL), Twitter (NYSE: TWTR), and Intel (NASDAQ:INTC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.
Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company's Investigational Anti-PD-1 Antibody, at ESMO 2014
Business Wire - Tue Sep 02, 7:30AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company's investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 - 30. Data on pembrolizumab are planned to be presented in five advanced solid tumor types, including the first presentation of data evaluating pembrolizumab for the treatment of gastric and bladder (urothelial tract) cancers. Three late-breaking abstracts have been accepted for oral presentation.
Great Cholesterol Drug Data From Regeneron Pharmaceuticals Inc. and Sanofi SA, but Read the Fine Pri
Brian Orelli, The Motley Fool - Motley Fool - Tue Sep 02, 7:00AM CDT
Amgen is leading the race to bring the first anti-PCSK9 cholesterol-lowering drug on the market, having submitted its application for evolocumab to the FDA last week. But Regeneron Pharmaceuticals and Sanofi look like they might have the...
Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical
M2 - Mon Sep 01, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfkpw2/global_multiple) has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. The Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis. One of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis. According to the report, the launch of products for treating multiple sclerosis is expected to drive the market during the forecast period of 2013-2018. There is a lucrative space for companies that can address the issue of unmet medical needs in the market. Further, the report states that one of the major challenges in the Global Multiple Sclerosis Drugs market is the unknown etiology of the disease. This has made difficult for medical researchers to develop drugs that target the main source of the disease. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Market Drivers/Challenges/Trends - Unmet Medical Needs - Unknown Etiology of the Disease - Introduction of Disease-modifying Drugs Key Vendors - Bayer - Biogen Idec - Merck Serono - Novartis - Teva Pharmaceutical Other Prominent Vendors - AB Science - Abbvie - Acorda - Active Biotech - GlaxoSmithKline - Glenmark - Mitsubishi Tanabe - Opexa - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/vf...l_multiple
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Dow 30 Stock Roundup: UTX Reiterates Guidance, BA Wins $8.8B Order - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Aug 29, 10:16AM CDT
The Dow had a mixed week following mixed earnings results and concerns about the situation in Ukraine.
Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical
PR Newswire Europe - Fri Aug 29, 7:37AM CDT
DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/z9b74c/global_multiple] has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/z9b74c/global_multiple] report to their offering.
